Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Molecular and cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Res. 2023 Nov 15;83(22):3726-3738. doi: 10.1158/0008-5472.CAN-23-0783.
The peritoneal cavity is a common site of gastric adenocarcinoma (GAC) metastasis. Peritoneal carcinomatosis (PC) is resistant to current therapies and confers poor prognosis, highlighting the need to identify new therapeutic targets. CD47 conveys a "don't eat me" signal to myeloid cells upon binding its receptor signal regulatory protein alpha (SIRPα), which helps tumor cells circumvent macrophage phagocytosis and evade innate immune responses. Previous studies demonstrated that the blockade of CD47 alone results in limited clinical benefits, suggesting that other target(s) might need to be inhibited simultaneously with CD47 to elicit a strong antitumor response. Here, we found that CD47 was highly expressed on malignant PC cells, and elevated CD47 was associated with poor prognosis. Galectin-3 (Gal3) expression correlated with CD47 expression, and coexpression of Gal3 and CD47 was significantly associated with diffuse type, poor differentiation, and tumor relapse. Depletion of Gal3 reduced expression of CD47 through inhibition of c-Myc binding to the CD47 promoter. Furthermore, injection of Gal3-deficient tumor cells into either wild-type and Lgals3-/- mice led to a reduction in M2 macrophages and increased T-cell responses compared with Gal3 wild-type tumor cells, indicating that tumor cell-derived Gal3 plays a more important role in GAC progression and phagocytosis than host-derived Gal3. Dual blockade of Gal3 and CD47 collaboratively suppressed tumor growth, increased phagocytosis, repolarized macrophages, and boosted T-cell immune responses. These data uncovered that Gal3 functions together with CD47 to suppress phagocytosis and orchestrate immunosuppression in GAC with PC, which supports exploring a novel combination therapy targeting Gal3 and CD47.
Dual inhibition of CD47 and Gal3 enhances tumor cell phagocytosis and reprograms macrophages to overcome the immunosuppressive microenvironment and suppress tumor growth in peritoneal metastasis of gastric adenocarcinoma.
胃腺癌(GAC)转移的常见部位是腹腔。腹膜癌病(PC)对目前的治疗方法有抵抗力,并导致预后不良,这凸显了需要确定新的治疗靶点。CD47 与信号调节蛋白α(SIRPα)结合后,向髓样细胞发出“不要吃我”的信号,这有助于肿瘤细胞逃避巨噬细胞吞噬作用并逃避先天免疫反应。先前的研究表明,单独阻断 CD47 仅导致有限的临床益处,这表明需要同时抑制其他靶标(S)与 CD47 一起发挥强大的抗肿瘤反应。在这里,我们发现 CD47 在恶性 PC 细胞上高度表达,并且 CD47 的升高与预后不良相关。半乳糖凝集素-3(Gal3)的表达与 CD47 的表达相关,Gal3 和 CD47 的共表达与弥漫型、低分化和肿瘤复发显著相关。Gal3 的耗竭通过抑制 c-Myc 与 CD47 启动子结合来降低 CD47 的表达。此外,与 Gal3 野生型肿瘤细胞相比,将 Gal3 缺陷型肿瘤细胞注入野生型和 Lgals3-/-小鼠中,导致 M2 巨噬细胞减少和 T 细胞反应增加,这表明肿瘤细胞衍生的 Gal3 在 GAC 进展和吞噬作用中比宿主衍生的 Gal3 发挥更重要的作用。Gal3 和 CD47 的双重阻断协同抑制肿瘤生长,增加吞噬作用,重塑巨噬细胞,并增强 T 细胞免疫反应。这些数据揭示了 Gal3 与 CD47 一起发挥作用,以抑制吞噬作用并在伴有 PC 的 GAC 中协调免疫抑制,这支持探索针对 Gal3 和 CD47 的新型联合治疗方法。
CD47 和 Gal3 的双重抑制增强了肿瘤细胞的吞噬作用,并重塑了巨噬细胞,以克服免疫抑制微环境,抑制胃腺癌腹膜转移中的肿瘤生长。